Rutaecarpine Inhibits Intimal Hyperplasia in A Balloon-Injured Rat Artery Model

Overview

Journal Chin J Integr Med

Date 2017 Sep 2

PMID 28861806

Citations 4

Authors

Yang Xu

Xiu-Ping Chen

Feng Zhang

Hua-Hua Hou

Jing-Yi Zhang

Shu-Xian Lin

An-Sheng Sun

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effect and potential mechanisms of rutaecarpine (Rut) in a rat artery balloon-injury model.

Methods: The intimal hyperplasia model was established by rubbing the endothelia with a balloon catheter in the common carotid artery (CCA) of rats. Fifty rats were randomly divided into five groups, ie. sham, model, Rut (25, 50 and 75 mg/kg) with 10 rats of each group. The rats were treated with or without Rut (25, 50, 75 mg/kg) by intragastric administration for 14 consecutive days following injury. The morphological changes of the intima were evaluated by hematoxylin-eosin staining. The expressions of proliferating cell nuclear antigen (PCNA) and smooth muscle (SM) α-actin in the ateries were assayed by immunohistochemical staining. The mRNA expressions of c-myc, extracellular signal-regulated kinase 2 (ERK2), MAPK phosphatase-1 (MKP-1) and endothelial nitric oxide synthase (eNOS) were determined by real-time reverse transcription-polymerase chain reaction. The protein expressions of MKP-1 and phosphorylated ERK2 (p-ERK2) were examined by Western blotting. The plasma contents of nitric oxide (NO) and cyclic guanosine 3',5'-monophosphate (cGMP) were also determined.

Results: Compared with the model group, Rut treatment significantly decreased intimal thickening and ameliorated endothelial injury (P<0.05 or P<0.01). The positive expression rate of PCNA was decreased, while the expression rate of SM α-actin obviously increased in the vascular wall after Rut (50 and 75 mg/kg) administration (P<0.05 or P<0.01). Furthermore, the mRNA expressions of c-myc, ERK2 and PCNA were downregulated while the expressions of eNOS and MKP-1 were upregulated (P<0.05 or P<0.01). The protein expressions of MKP-1 and the phosphorylation of ERK2 were upregulated and downregulated after Rut (50 and 75 mg/kg) administration (P<0.05 or P<0.01), respectively. In addition, Rut dramatically reversed balloon injury-induced decrease of NO and cGMP in the plasma (P<0.05 or P<0.01).

Conclusion: Rut could inhibit the balloon injury-induced carotid intimal hyperplasia in rats, possibly mediated by promotion of NO production and inhibiting ERK2 signal transduction pathways.

Citing Articles

Computational screening and molecular docking of compounds from Traditional Chinese Medicine (TCM) by targeting DNA topoisomerase I to design potential anticancer drugs.

Shimu M PLoS One. 2024; 19(9):e0310364.

PMID: 39264927 PMC: 11392414. DOI: 10.1371/journal.pone.0310364.

Traditional Chinese medicine Euodiae Fructus: botany, traditional use, phytochemistry, pharmacology, toxicity and quality control.

Xiao S, Xu X, Chen W, Xin J, Yuan W, Zu X Nat Prod Bioprospect. 2023; 13(1):6.

PMID: 36790599 PMC: 9931992. DOI: 10.1007/s13659-023-00369-0.

Rutaecarpine Increases Nitric Oxide Synthesis via eNOS Phosphorylation by TRPV1-Dependent CaMKII and CaMKKβ/AMPK Signaling Pathway in Human Endothelial Cells.

Lee G, Kim C, Zheng C, Jin S, Kim J, Lee S Int J Mol Sci. 2021; 22(17).

PMID: 34502308 PMC: 8431268. DOI: 10.3390/ijms22179407.

Chemokine-like factor 1 (CKLF1) aggravates neointimal hyperplasia through activating the NF-κB /VCAM-1 pathway.

Liu X, Qu C, Zhang Y, Fang J, Teng L, Zhang R FEBS Open Bio. 2020; 10(9):1880-1890.

PMID: 32741140 PMC: 7459414. DOI: 10.1002/2211-5463.12942.

References

Wu X, Liu W, Jiang H, Chen J, Wang J, Zhu R . Kindlin-2 siRNA inhibits vascular smooth muscle cell proliferation, migration and intimal hyperplasia via Wnt signaling. Int J Mol Med. 2015; 37(2):436-44. DOI: 10.3892/ijmm.2015.2429. View

Jia S, Hu C . Pharmacological effects of rutaecarpine as a cardiovascular protective agent. Molecules. 2010; 15(3):1873-81. PMC: 6257227. DOI: 10.3390/molecules15031873. View

Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C . Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998; 97(13):1274-81. DOI: 10.1161/01.cir.97.13.1274. View

Yu P, Ferrari G, Pirelli L, Gulkarov I, Galloway A, Mignatti P . Vascular injury and modulation of MAPKs: a targeted approach to therapy of restenosis. Cell Signal. 2007; 19(7):1359-71. DOI: 10.1016/j.cellsig.2007.03.002. View

Moldovan G, Pfander B, Jentsch S . PCNA, the maestro of the replication fork. Cell. 2007; 129(4):665-79. DOI: 10.1016/j.cell.2007.05.003. View

Hogg M, Varu V, Vavra A, Popowich D, Banerjee M, Martinez J . Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status. Free Radic Biol Med. 2011; 50(9):1065-74. PMC: 3070831. DOI: 10.1016/j.freeradbiomed.2011.01.016. View

Owens G . Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995; 75(3):487-517. DOI: 10.1152/physrev.1995.75.3.487. View

Iatropoulos M, Williams G . Proliferation markers. Exp Toxicol Pathol. 1996; 48(2-3):175-81. DOI: 10.1016/S0940-2993(96)80039-X. View

Thiel W, Esposito C, Dickey D, Dassie J, Long M, Adam J . Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther. 2016; 24(4):779-87. PMC: 4886937. DOI: 10.1038/mt.2015.235. View

10.

Li J, Peng J, Xiao L, Zhang Y, Liao M, Li X . Reversal of isoprenaline-induced cardiac remodeling by rutaecarpine via stimulation of calcitonin gene-related peptide production. Can J Physiol Pharmacol. 2010; 88(10):949-59. DOI: 10.1139/y10-067. View

11.

Sheu J, Hung W, Wu C, Lee Y, Yen M . Antithrombotic effect of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa, on platelet plug formation in in vivo experiments. Br J Haematol. 2000; 110(1):110-5. DOI: 10.1046/j.1365-2141.2000.01953.x. View

12.

OConnor D, OBrien T . Nitric oxide synthase gene therapy: progress and prospects. Expert Opin Biol Ther. 2009; 9(7):867-78. DOI: 10.1517/14712590903002047. View

13.

Sheu J, Hung W, Lee Y, Yen M . Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Eur J Pharmacol. 1996; 318(2-3):469-75. DOI: 10.1016/s0014-2999(96)00789-3. View

14.

Hu C, Xiao L, Deng H, Li Y . The cardioprotection of rutaecarpine is mediated by endogenous calcitonin related-gene peptide through activation of vanilloid receptors in guinea-pig hearts. Planta Med. 2002; 68(8):705-9. DOI: 10.1055/s-2002-33794. View

15.

Wang L, Zheng J, Du Y, Huang Y, Li J, Liu B . Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with alpha(7)beta(1) integrin. Circ Res. 2009; 106(3):514-25. DOI: 10.1161/CIRCRESAHA.109.202762. View

16.

Li Y, McRobb L, Khachigian L . Inhibition of intimal thickening after vascular injury with a cocktail of vascular endothelial growth factor and cyclic Arg-Gly-Asp peptide. Int J Cardiol. 2016; 220:185-91. DOI: 10.1016/j.ijcard.2016.06.300. View

17.

Li Y, Zhang F, Gong Q, Wu Q, Yu L, Sun A . Rutaecarpine inhibits angiotensin II-induced proliferation in rat vascular smooth muscle cells. Chin J Integr Med. 2013; 20(9):682-7. DOI: 10.1007/s11655-013-1198-4. View

18.

Li D, Peng J, Xin H, Luo D, Zhang Y, Zhou Z . Calcitonin gene-related peptide-mediated antihypertensive and anti-platelet effects by rutaecarpine in spontaneously hypertensive rats. Peptides. 2008; 29(10):1781-8. DOI: 10.1016/j.peptides.2008.06.010. View

19.

Wang G, Wu X, Chen C, Lin L, Huang Y, Shan J . Vasorelaxing action of rutaecarpine: effects of rutaecarpine on calcium channel activities in vascular endothelial and smooth muscle cells. J Pharmacol Exp Ther. 1999; 289(3):1237-44. View

20.

Shapiro P, Ahn N . Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1). J Biol Chem. 1998; 273(3):1788-93. DOI: 10.1074/jbc.273.3.1788. View